NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

Novo Nordisk is increasing production of its weight-loss drug Wegovy amid rising demand, investing significantly in manufacturing to achieve full capacity by 2026.

The FDA has addressed shortages for Eli Lilly's Zepbound and Mounjaro, impacting Novo Nordisk's Wegovy. Compounding pharmacies must stop making unauthorized versions within 90 and 60 days.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.